Telomerase mediated telomere altering compounds
US10463685B2 · kind B2 · utility
4Cited by
0References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 8, 2014 |
| Grant date | Nov 5, 2019 |
| Priority date | — |
| Expiry date | Apr 8, 2034 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods for treating a telomerase-expressing cell characterized by an over-activation of telomerase in a subject in need thereof comprising administering a pharmaceutical composition comprising a first amount of a 6-mercaptopurine analog, and a second amount of a telomerase inhibitor, wherein the first amount and the second amount together comprises an amount effective to reduce stability of telomere length and to induce cell death in the telomerase-expressing cell are provided. The methods can be used to treat patients with lung cancer, colon cancer, or cervical cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.